pCPA Activity Overview
| Status | Total Negotiations | Summary |
|---|---|---|
| Active Negotiations | 50 | Non-oncology: 28 Oncology: 22 |
| Under Consideration for Negotiation | 17 | Non-oncology: 8 Oncology: 9 |
| Completed Negotiations | 902 | With Letter of Intent: 778 Without agreement: 124 |
| Negotiations That Were Not Pursued | 113 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
| Brand Name | Manufacturer | Indication | Engagement Date |
|---|---|---|---|
| Welireg | Merck Canada Inc. | For the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). | |
| Qalsody | Biogen Canada Inc. | Amyotrophic Lateral Sclerosis (ALS) | |
| Hepcludex | Gilead Sciences Canada Inc. | Chronic hepatitis delta virus (HDV) infection | |
| Okedi | Bausch Health, Canada Inc. | Schizophrenia in Adults | |
| Nemluvio | Galderma Canada Inc. | Prurigo nodularis | |
| Nemluvio | Galderma Canada Inc. | For the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older who are candidates for systemic therapy. | |
| Enhertu | AstraZeneca Canada Inc. | For the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the meta | |
| Andembry | CSL Behring Canada Inc. | Hereditary Angioedema | |
| Anzupgo | LEO Pharma Inc. | Chronic hand eczema | |
| Zepzelca (active pTAP negotiation) | Jazz Pharmaceuticals Canada Inc. | For the treatment of adult patients with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy. | |
| Opzelura | Incyte Biosciences Canada Corporation | Atopic dermatitis |